<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3887">
  <stage>Registered</stage>
  <submitdate>22/03/2013</submitdate>
  <approvaldate>22/03/2013</approvaldate>
  <nctid>NCT01820637</nctid>
  <trial_identification>
    <studytitle>Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project</studytitle>
    <scientifictitle>Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent</scientifictitle>
    <utrn />
    <trialacronym>MAJESTIC</trialacronym>
    <secondaryid>S2049</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atherosclerosis of Native Arteries of the Extremities</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)

Experimental: Test device arm (DES SFA) - Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)


Treatment: devices: The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
Drug-eluting SFA self-expanding stent

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary patency - Primary patency of target lesion at 9-months assessed by duplex ultrasound as adjudicated by an independent core laboratory.</outcome>
      <timepoint>9-months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects age 18 and older

          -  Subject (or Legal Guardian if applicable) has signed the consent form and is willing
             and able to provide consent before any study-specific tests or procedures are
             performed and agrees to attend all required follow-up visits

          -  Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3 or 4

          -  Stenotic, restenotic (from angioplasty only, previous treatment with drug coated
             balloon is not allowed) or occlusive lesion(s) located in the native superficial
             femoral artery or proximal popliteal artery:

               1. Degree of stenosis =70% by visual angiographic assessment

               2. Vessel diameter = 4 and = 6mm

               3. Total lesion length (or series of lesions) =30 mm and =110 mm

                    -  (Note: tandem lesions may be treated, provided that the tandem lesion
                       segment can be covered with only one stent)

               4. Target lesion located at least three centimeters above the inferior edge of the
                  femur

          -  Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with
             at least one of three vessels patent (&lt;50% stenosis) to the ankle or foot</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>57</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>20/02/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <postcode> - Camperdown</postcode>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna, Austria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Dendermonde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Tienen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Flensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otahuhu</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable
      performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal
      Artery (PPA) lesions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01820637</trialwebsite>
    <publication>Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011 Oct 1;4(5):495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324. Epub 2011 Sep 27.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stefan Müller-Hülsbeck, Prof.</name>
      <address>Ev. Luth. Diakonissenanstalt Flensburg</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>